Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, NORTHWEST BIOTHERAPEUTICS INC reported revenue of $1M, down 0.3% year over year. Operating margin was -4347.9% and net margin -4365.9%, on a free-cash-flow margin of -3357.5% with capital expenditure at 109.1% of revenue. Every figure is computed directly from NWBO's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $1M | -4347.9% | -4365.9% |
| FY2024 | $1M | -4812.4% | -6062.1% |
| FY2023 | $2M | -2873.1% | -3240.1% |
| FY2022 | $2M | -3991.7% | -6240.8% |
| FY2021 | $1M | -5244.0% | 17823.5% |
How does NWBO compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.